Home » Health » Rise of drug-resistant 'superbugs': why pharma companies are to blame

Rise of drug-resistant 'superbugs': why pharma companies are to blame

Vishakh Unnikrishnan | Updated on: 10 February 2017, 1:46 IST

'Superbugs' is the colloquial name given to bacteria that are resistant to antibiotics. And it's a matter that must be talked about, because every year, nearly one million people die worldwide due to drug resistant infections. In comparison, over 1.2 million people die of HIV/AIDS every year.

The figure is projected to climb to 10 million by the middle of this century, with medical experts now placing drug resistance in the same bracket as the HIV/AIDS crisis.

In India, 'antibiotic-resistant neonatal infections' cause the deaths of nearly 60,000 newborns each year.

While there are a variety of reasons contributing to the rise of 'superbugs', the heart of the issue lies with global pharmaceutical companies, whose role it is to ensure anitbiotics are manufactured in factories with adequate disposal and treatment facilities.

However, a recent study by Changing Markets, an environment lobby group, titled 'Superbugs in Supply Chain', shows that many large pharma companies in India are doing exactly the opposite.

A pan-India problem

The report shows that manufacturers do not adequately treat waste products, with the result that superbugs are released into the local environment, usually as waste water that acts as a 'reservoirs' of antibiotic-resistant bacteria.

The study points to one company in particular, Hyderabad-based Aurobindo, as one of the worst offenders.

In total, 34 sites were tested, of which 16 were found to be harbouring antibiotics-resistant bacteria. The investigation team took control samples from water sources in each of the four regions visited. This included sewage treatment plants receiving effluents from drug production facilities, and water bodies in the vicinity.

The investigation team, while inspecting the plants, concluded that the problem affected states across the country.

Of the 16 infected sites, four plants belonged to large corporations that manufacture and export active pharmaceutical ingredient (API) - the fundamental ingredient in any drug. These were Aurobindo Pharma (two in Hyderabad), Orchid Chemicals (Chennai) and Asiatic Drugs and Pharmaceuticals (Delhi).

The study concluded that these factories were found to be 'resistance hotspots', a breeding ground for superbugs.

At Asiatic's Delhi plant, the investigation team took samples from dirty-looking and malodorous waste-water in a gully at the front corner of the plant, fed by pipes leading from inside the site.

Photo: changingmarkets.org

The samples showed resistance to six major antibiotics, which indicates resistance to three major classes of antibiotics, namely cephalosporins, carbapenems and fluoroquinolones.

Cephalosporins are antibiotics used to treat a variety of diseases including pneumonia and meningitis. In 2013, meningitis affected 16 million people worldwide, and resulted in 303,000 deaths.

Carbapenems are antibiotics used majorly to treat urinary tract infections and also pneumonia.

Fluoroquinolones are used to treat chronic prostatitis, tuberculosis, urinary tract infections, sinusitis and meningitis.

The study indicates that this resistance is caused largely due to industries not following regulations, despite decades of campaigning by NGOs and legal action taken by high courts and even the Supreme Court.

Regulations targeting pharmaceutical industry have also become lax, with the government lifting various restrictions, especially on plan expansion in August.

The report concludes that irresponsible and even illegal manufacturing practices, which have blighted the region for decades, are contributing to the rise of superbugs.

Asiatic and Aurobindo Pharma did not reply to emailed queries sent by Catch. Orchid Chemicals rebuffed the report, and stated that it follows all norms set by the state and the Centre.

Lobbying power

India is home to thousands of pharmaceutical manufacturing units, and is a major hub of drug production. It supplies around one-fifth of the world's generic drugs, netting about $15 billion in revenues in 2014.

This reflects the lobbying power of the pharma industry, and why the government should ensure it follows norms to ensure adequate treatment plants in various factories.

A Reuters report in September showed that the Kazhipally lake in Medak, Telangana, is now a 'superbug hotspot', and the blame lies with mega pharmaceutical corporations in the vicinity that produce cheap drugs. The report quotes retired factory staff of these plants admitting that untreated chemical effluents were dumped illegally, especially into boreholes inside these plants, and even into local water bodies at night.

Edited by Shreyas Sharma

More in Catch

Antibiotic resistance is a real threat. India needs to wake up to it now

What will happen when antibiotics stop working?

Apocalypse now: in less than 10 years, antibiotics may be useless

First published: 28 October 2016, 11:31 IST
Vishakh Unnikrishnan @sparksofvishdom

A graduate of the Asian College of Journalism, Vishakh tracks stories on public policy, environment and culture. Previously at Mint, he enjoys bringing in a touch of humour to the darkest of times and hardest of stories. One word self-description: Quipster.